Discovery of (<i>E</i>)-3-((Styrylsulfonyl)methyl)pyridine and (<i>E</i>)-2-((Styrylsulfonyl)methyl)pyridine Derivatives as Anticancer Agents: Synthesis, Structure–Activity Relationships, and Biological Activities
作者:Tiangong Lu、Aik Wye Goh、Mingfeng Yu、Julian Adams、Frankie Lam、Theodosia Teo、Peng Li、Ben Noll、Longjin Zhong、Sarah Diab、Osama Chahrour、Anran Hu、Abdullahi Y. Abbas、Xiangrui Liu、Shiliang Huang、Christopher J. Sumby、Robert Milne、Carol Midgley、Shudong Wang
DOI:10.1021/jm4019614
日期:2014.3.27
exposure for biological activity in patients. We have identified two novel series of styrylsulfonyl-methylpyridines. Lead compounds 8, 9a, 18 and 19a are highly potent mitotic inhibitors and selectively cytotoxic to cancer cells. Impressively, these compounds possess excellent pharmaceutical properties and two lead drug candidates 9a and 18 demonstrated antitumor activities in animal models.
ON01910.Na是一种高效的抗癌剂,可诱导有丝分裂阻滞和细胞凋亡。ON01910在癌症患者中的临床研究显示出疗效以及令人印象深刻的安全性。尽管ON01910对癌细胞具有高活性,但口服利用率低,需要连续静脉输注或多克剂量才能确保患者充分的药物暴露以实现其生物学活性。我们已经确定了两个新颖的苯乙烯基磺酰基-甲基吡啶系列。铅化合物8,图9A,18和19A是高度有效的有丝分裂抑制剂和选择性的细胞毒性,以癌细胞。令人印象深刻的是,这些化合物具有出色的药物特性和两个候选候选药物9a还有18个在动物模型中证明了抗肿瘤活性。